EPHA2 and urinary bladder cancer: The activity of EphA2-ILs-DTXp in combination with gemcitabine was compared to the combination of equitoxic dosing of free docetaxel with gemcitabine in an additional EphA2-positive bladder cancer model (BL417362) (Figures S1D and S5).